Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12165071 | 0.85 | CYP3A4 (0.38) | NOS3NOS1NOS2CYP3A4MAPT | |
| SCHEMBL12164922 | 0.83 | NOS3 (0.36) | NOS3NOS1NOS2CYP3A4MAPT | |
| SCHEMBL12165155 | 0.81 | NOS3 (0.36) | NOS3NOS1NOS2CYP3A4 | |
| SCHEMBL12165406 | 0.80 | L3MBTL1 (0.32) | NOS3NOS1NOS2 | |
| SCHEMBL12165408 | 0.80 | NOS3 (0.40) | NOS3NOS1NOS2MAPTSMN1; SMN2 | |
| SCHEMBL12165095 | 0.80 | NOS3 (0.34) | NOS3NOS1NOS2CYP3A4 | |
| SCHEMBL12165370 | 0.79 | AGPAT2 (0.39) | MAPTRAB9AGAA | |
| SCHEMBL12165371 | 0.79 | ADORA3 (0.35) | NOS3NOS1NOS2SMN1; SMN2 | |
| SCHEMBL12165286 | 0.79 | NOS3 (0.38) | NOS3NOS1NOS2SMN1; SMN2 | |
| SCHEMBL12165118 | 0.77 | NOS3 (0.36) | NOS3NOS1NOS2CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980926-B2 | 2-aminoindole compounds and methods for the treatment of malaria | GENZYME CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980926-B2 | 2-aminoindole compounds and methods for the treatment of malaria | GENZYME CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-09-13 | — | — | US | disclosed |
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | PNMT, AADAT, INMT | NOS3 1338/4885NOS1 2105/4885NOS2 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.